FOXO1 mutations however, have been associated with poor prognosis and diminished treatment response; FOXO1 missense mutations affecting the DBD and the Thr24 mutation (Figure 1), led to poorer overall survival of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and is associated with poor prognosis in DLBCL (113). Here, FOXO1 is linked to diffuse large B-cell lymphoma.